A Multivariate Genomic Investigation of the Externalizing Spectrum and Suicide

Risk

Peter B. Barr, PhD [1-4], Mallory Stephenson, PhD [5], Holly E. Poore, PhD [6,7], Chris Chatzinakos, PhD [1-3], Xuejun Qin, PhD [8-10], Allison E. Ashley-Koch, PhD [8-10], Elizabeth R. Hauser, PhD [8-10], Jacquelyn L. Meyers, PhD [1-3], Roseann E. Peterson, PhD [1-3], Sandra Sanchez-Roige, PhD [11-13], Travis T. Mallard, PhD [14,15], Danielle M. Dick, PhD [6,7], K. Paige Harden, PhD [16,17], COGA Collaborators*, Mihaela Aslan, PhD [18,19], Philip D. Harvey, PhD [20,21], Jean C. Beckham, PhD [8-10], Tim B. Bigdeli, PhD [†1-3], and Nathan A. Kimbrel, PhD [†8-10], on behalf of the VA Million Veteran Program (MVP) and Cooperative Studies Program (CSP) #572

1. VA New York Harbor Healthcare System, Brooklyn, NY
2. Department of Psychiatry and Behavioral Sciences, SUNY Downstate Health Sciences University, Brooklyn, NY
3. Institute for Genomics in Health (IGH), SUNY Downstate Health Sciences University, Brooklyn, NY
4. Department of Community Health Sciences, School of Public Health, SUNY Downstate Health Sciences University, Brooklyn, NY
5. Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, VA.
6. Department of Psychiatry, Robert Wood Johnson Medical School, Rutgers University, Piscataway, NJ
7. Rutgers Addiction Research Center, Rutgers University, Piscataway, NJ
8. Durham VA Health Care System, Durham, NC
9. VA Mid-Atlantic Mental Illness Research, Education and Clinical Center, Durham, NC
10. Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC
11. Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
12. Institute for Genomic Medicine, University of California San Diego, La Jolla, CA, USA
13. Division of Genetic Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
14. Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
15. Department of Psychiatry, Harvard Medical School, Boston, MA, USA
16. Department of Psychology, University of Texas at Austin, Austin, TX
17. Population Research Center, University of Texas at Austin, Austin, TX
18. Clinical Epidemiology Research Center (CERC), VA Connecticut Healthcare System, West Haven, CT
19. Yale University School of Medicine, New Haven, CT
20. Research Service, Bruce W. Carter Miami Veterans Affairs (VA) Medical Center, Miami, FL
21. University of Miami Miller School of Medicine, Miami, FL

*A list of authors and their affiliations appears at the end of the paper
† These authors jointly supervised this work

Corresponding author: Peter B. Barr
450 Clarkson Ave, MSC 1203, Brooklyn, NY 11203
e-mail: peter.barr@downstate.edu.

Abstract: 326 words
Word count: 3,452 words
2 tables; 4 figures
Running Header: Externalizing and Suicide Risk

ABSTRACT

Suicidal thoughts and behaviors originate from heterogeneous mechanisms, including behavioral disinhibition characteristic of "externalizing" disorders (e.g., substance use disorders, antisocial personality disorder, etc.). Prior work has demonstrated strong genetic overlap between externalizing and suicide attempts. In the current analysis, we investigate the co-occurrence between a broader array of suicide phenotypes (i.e., suicide deaths, non-fatal attempts, suicidal ideation) and the externalizing spectrum using data from the Million Veteran Program (MVP) Cohort. We leverage the large-scale MVP database to (1) estimate a latent genomic factor for externalizing comprised of MVP data (MVP-EXT) using genomic structural equation modeling (GenomicSEM), (2) validate these results against prior externalizing models and other traits, (3) examine the genetic overlap between externalizing and suicide outcomes using multiple approaches (e.g., genetic correlations, polygenic scores, and post mortem brain tissue of suicide deaths), and (4) explore whether phenotypic externalizing is prospectively associated with death by suicide. We identify 155 loci in our meta-analysis of European-like (EUR-like, N = 310,498) and African-like (AFR-like, N = 99,949) MVP participants. MVP-EXT showed a strong genetic correlation with a prior, non-MVP externalizing factor (rG = 0.87, 95% CI = 0.83, 0.91) and suicide attempt in both EUR-like (rG = 0.67, 95% CI = 0.60, 0.74) and AFR-like (rG = 0.62, 95% CI = 0.42, 0.81) veterans. MVP-EXT polygenic scores were associated with suicidal ideation (OR = 1.09, 95% CI = 1.05, 1.13) and suicide attempts (OR = 1.20, 95% CI = 1.13, 1.27) in independent cohorts. MVP-EXT associated genes showed significant enrichment particularly within inhibitory neurons in suicide deaths compared to deaths from other causes. A phenotypic score for externalizing was prospectively associated with death by suicide in MVP (HR = 1.39, 95% CI = 1.33, 1.45). In total, our results reiterate that, while the relation between suicide with internalizing disorders has generally received more attention, externalizing is an important risk factor for suicide related behaviors. Greater attention should be paid to these problems as potential antecedents of suicide-related behaviors.

INTRODUCTION

Suicide remains a leading preventable cause of death, Suicide rates in the United States increased ~37% between 2000 and 2022. Deaths by suicide have contributed significantly to the decline in U.S. life expectancy, alongside other "deaths of despair"[1,2]. In addition to suicide deaths, the number of U.S. adults reporting a lifetime suicide attempt has increased in recent birth cohorts[3]. Suicide attempts are more prevalent in those with co-occurring psychiatric problems. For example, among those with an alcohol use disorder (AUD), the prevalence of lifetime suicide attempt is more than triple the prevalence of the general population (17.5%)[4] and 40% of those seeking treatment for AUD report at least one suicide attempt[5–8]. Additionally, meta-analyses of attention-deficit/hyperactivity disorders (ADHD) and suicide related outcomes reveal strong associations with attempt, plans, and death by suicide[9]. While mood-related problems are important risk factors for suicide present in these comorbid psychiatric problems[10], other mechanisms related to behavioral disinhibition and impulsivity are also important for suicide risk.

Disorders related to behavioral disinhibition (e.g., substance use disorders, ADHD, etc.), generally referred to as externalizing disorders[11,12], share a common etiology[13]. Twin and family studies suggest that the liability for externalizing is highly heritable[14,15]. Recent multivariate genome wide association studies (GWAS) have found robust evidence for shared genomic factors for externalizing[16–18]. This genetic liability to externalizing also is genetically correlated with suicide attempt[16,19], and externalizing polygenic scores (PGS) are associated with suicide-related outcomes[20,21]. Moreover, cases of death by suicide were enriched for genomic risk for a variety of traits related to externalizing, including AUD and other mental health problems[22]. However, we do not yet fully understand the nature of genetic overlap between externalizing and suicide-related outcomes.

In the current analysis, we explore the overlap between the externalizing spectrum and suicide-related outcomes in the Million Veteran Program (MVP) cohort. First, we validated a latent genomic factor for externalizing in MVP (MVP-EXT), comparing results to a previously published genome wide

association study (GWAS)[16]. Next, compared the overlap of MVP-EXT and suicide-related outcomes using genetic correlations and polygenic scores in external cohorts to further explore these associations. Third, we used GWAS results to explore cell type enrichment in postmortem brain tissue of individuals who died by suicide compared to non-suicide deaths. Lastly, we performed a prospective analysis that evaluated the relationship between externalizing from electronic health records (EHR) and suicide mortality within the MVP cohort.

METHODS

The Million Veteran Program Cohort (MVP)

MVP links genomic laboratory testing, survey-based self-report data, and EHR data, with the goal of enhancing precision medicine initiatives[23]. Enrolled participants reflect the population that utilizes the VA, with over-representation of older and male individuals, as well as higher rates of multiple morbidities and chronic conditions related to externalizing compared to the general population[24,25]. Participants are active users of the VA healthcare system. Informed consent and authorization per the Health Insurance Portability and Accountability Act (HIPAA) were the only inclusion criteria. Once enrolled, participants' EHR data are linked with their genetic data. The current analysis uses Release 4 of MVP data [February 2022] and was approved by the VA Central Institutional Review Board (IRB). All participants provided written informed consent.

MVP participants were genotyped on the MVP 1.0 Axiom array[26]. Genetic similarity of participants was classified using the HARE method[27], which harmonizes the closest inferred ancestral population with self-reported race and ethnicity. Genotypic data were imputed to the Trans-Omics for Precision Medicine (TOPMed) reference panel[28]. We used data from the N = 467,101 veterans most similar to European reference panels (EUR-like) and the N = 124,717 veterans most similar to African reference panels (AFR-like) groups, as these had adequate statistical power for inclusion in the multivariate GWAS.

Genome Wide Association Study (GWAS) Phenotypes

We collated GWAS on externalizing-related traits within MVP that matched those in Externalizing

Consortium GWAS (EXT1.0)[16] as closely as possible when available. Our outcomes for the GWAS

included in the multivariate models came from electronic health records (EHR) and the MVP Baseline

Survey. EHR data were converted to phecodes, which are clusters of ICD-9/10-CM codes[29,30]. We

defined a lifetime diagnosis for any given phecode as two or more occurrences of that phecode in their

EHR, consistent with prior EHR analyses[31,32]. We examined all lifetime diagnoses without exclusion for

overlap. We used phecodes for *Substance addiction and disorders* (Phecode 316, DUD), *Alcohol-*

related disorders (Phecode 317, AUD), *Tobacco use disorder* (Phecode 318, TUD), and *Attention*

deficit hyperactivity disorder (Phecode 313.1, ADHD). Questions for lifetime smoking (SMOK) and

binge drinking (BINGE) came from the Baseline Survey. We performed all univariate GWASs using

SAIGE[33] to adjust for relatedness and included age, gender, and the first 20 genetic principal

components as covariates (full details presented in the supplementary information). We filtered input

GWAS to MAF > 1% with imputation scores (INFO) ≥ 0.80.

Multivariate GWAS and downstream analyses

We performed a confirmatory factor analysis using GenomicSEM[34], which is robust to sample

overlap and sample-size imbalances[35]. Within the EUR-like population we used the provided linkage

disequilibrium (LD) scores[36]. For the AFR-like models, we used within-sample LD scores calculated

using cov-LDSC[37]. We carried the best fitting models forward for multivariate GWAS. We ran the

GWAS results from each population through FUMA (Functional Mapping and Annotation of GWAS)[38] to

identify independent loci ($r^2 < 0.1$) among genome-wide significant SNPs. To further quantify the

polygenic overlap between externalizing and suicide attempt, we applied bivariate MiXeR[39] which uses

a bivariate Gaussian mixture model to estimate the proportion of shared influential genetic variance

between two traits. Finally, we ran all results through a standard series of post-GWAS pipelines

(detailed in the supplementary information).

Single cell enrichment in post-mortem brain tissue of suicide deaths

To assess the collective expression of MVP-EXT related genes in those that died by suicide vs

those who died by other causes, we applied the single-cell Disease-Relevance Scoring (scDRS)[40]

method. Each potential candidate gene was weighted by its MAGMA[41] Z-score and adjusted for gene-

specific technical noise in single-cell data obtained from an extensive postmortem dataset, consisting of

450K cells from the dorsolateral prefrontal cortex (DLPFC) of 40 human donors from the VA's National

PTSD Brain Bank (NPBB)[42]. This sample consisted of 16 "control" individuals (non-suicides related

death) and 24 "cases" (confirmed suicide deaths, 12 with post-traumatic stress disorder and 12 with

major depressive disorder), described in detail elsewhere[43]. The scDRS approach produced cell-

specific raw disease scores. We generated 1,000 sets of cell-specific raw control scores using matched

control gene sets, ensuring consistency in gene set size, mean expression, and expression variance

with the candidate genes. Next, we normalized both the raw disease (e.g., suicide) and control scores

for each cell, resulting in normalized disease and control scores. We evaluated cell type-level

associations to identify broad cell types linked to the disease-status and to examine variability across

individual cells within each cell type. All results were adjusted for multiple testing using a false

discovery rate (FDR)[44].

Independent validation cohorts

We included two independent cohorts to perform follow-up analyses. First, the Collaborative

Study on the Genetics of Alcoholism (COGA) is a multi-site study of families densely affected with AUD

and community-ascertained comparison families[45–47]. Participants completed a poly-diagnostic

interview, the Semi-Structured Assessment for the Genetics of Alcoholism (SSAGA)[48]. The final

analytic sample consisted of 10,986 COGA participants with genetic data[49] ($N_{EUR-like}$ = 7,601; $N_{AFR-like}$ =

3,385). Second, the National Longitudinal Study of Adolescent to Adult Health (Add Health) is a

nationally representative study of participants in the United States recruited as adolescents and

followed into adulthood[50]. Our final analytic sample for Add Health consisted of 6,883 individuals (N_{EUR-}

$_{like}$ = 5,122; $N_{AFR-like}$ = 1,761).   Full descriptions of each cohort are presented in the supplemental

information.

Polygenic scores (PGS)

We estimated polygenic scores (PGS, aggregate measures of risk alleles weighted by GWAS

effect sizes) using PRS-CSx[51], which integrates GWAS summary statistics across multiple populations

to improve the predictive power of PGS in the populations that typically lack well-powered GWAS

results. Because of variation in allele frequencies and LD, PGS lose predictive accuracy when there is

mismatch between the population of the discovery GWAS and target sample, even within relatively

homogenous clusters[52]. PRS-CSx employs a Bayesian approach to correct GWAS summary statistics

for the non-independence of SNPs in the genome. We converted PGS into Z-scores.

Prospective investigation of externalizing and suicide-related mortality in EHR

Lastly, to better contextualize externalizing in relation to prospective risk for death by suicide,

we explored associations between externalizing and post-enrollment mortality. For each participant, we

created a count of the past 12-month externalizing EHR codes (relative to MVP enrollment) and

examined whether this count was associated with mortality via competing risk models[53]. We used

cause of death (COD) from the ICD codes provided in the linked National Death Index (NDI) data up to

December 2021 (v21, see Supplemental Table 1 for specific codes). The competing risk model allowed

us to accurately estimate the hazards for specific causes of death (e.g., suicide death) in the context of

competing causes (e.g., all other causes of death). We explored two competing risk models: 1) suicide-

death in the context of risk for all other causes of death, and 2) "deaths of despair" (suicide, alcohol,

and drug related deaths) in the context of risk for all other causes of death. We included age, gender,

and race-ethnicity (non-Hispanic White, Black/African-American, Hispanic or Latino/a/x, American

Indian/Alaskan Native, Asian, Native Hawaiian/Pacific Islander, multiracial, other race or ethnicity, or

missing race or ethnicity) as covariates. Analyses were conducted using the *survival* package in R[54,55].

It is important to note this paper includes language related to both race-ethnicity, which reflects

socially-constructed categories, and genetic similarity, which uses empirical assignment based on

available reference panels, because both are relevant for the current analyses. Prior work has

established that racism, discrimination, and adverse social conditions — to which marginalized

populations are disproportionally exposed — are relevant to suicide outcomes[56–58]. Additionally, we

follow best practices for handling genetic data from diverse populations to limit bias from population

stratification[59]. The inclusion of both concepts in no way endorses the notion that these reflect discrete

biological categories.

RESULTS

Creating and validating a latent externalizing factor in MVP

Table 1 presents the individual GWAS results for the 6 indicators in the multivariate GWAS. Our

final model for EUR-like veterans (N_{eff} = 310,498) contained all six indicators and showed reasonably

good fit to this model specification (Figure 1, Panel A; χ^2= 104.10, df = 7, p = 1.53x10^{-19}; CFI = 0.99,

SRMR = 0.06). For the AFR-like veterans, the genetic correlation between SMOK and TUD was

indistinguishable from one. We therefore retained only TUD, as it had greater statistical power. We also

replaced ADHD with the attention problems subscale of the Medical Outcomes Survey as a proxy

(MOS-ATTN, h^2_{SNP} [SE] = 0.033 [0.009], LDSC intercept = 1.003, Mean χ^2 = 1.038, λ_{GC} = 1.035, rG with

ADHD = 0.8) due to the low power of the ADHD indicator. The final model for AFR-like veterans (N_{eff} =

99,949) therefore, largely mirrored that of the EUR-like veterans with one fewer indicator (Figure 1,

Panel B; χ^2= 131.51, df = 8, p = 1.38x10^{-24}; CFI = 0.96, SRMR = 0.09).

Next, we performed multivariate GWASs within the EUR-like and AFR-like veterans, separately,

followed by an inverse-variance weighted fixed effects meta-analysis in METAL[60]. There were 155

independent genome wide significant loci in the meta-analysis, of which only 11 were significant Q-

SNPs (p <.05/155 = 3.23 x10^{-4}). Of the 138 of these loci that were present in EXT1.0, 94.2% (95% CI =

88.9%, 97.5%) were sign concordant and 116 (84.1%) of the loci were nominally significant (p < .05).

Finally, we took several steps to validate the MVP-EXT factor. First, we ran the genetic

correlation between MVP-EXT and EXT1.0, which was strong (rG = 0.87, 95% CI = 0.83, 0.91).

Second, we compared the genetic correlations of MVP-EXT and EXT1.0 with 93 external traits. The

correlation of rG effect size estimates was very strong (r = 0.96, 95% CI = 0.93, 0.97). Third, we tested

the association between the MVP-EXT PGS and a matched latent factor of externalizing in COGA and

Add Health. The PGS was associated with externalizing in each cohort, as well as on overall effect

(Beta $_{META}$ = 0.20, 95% CI = 0.18, 0.22). Taken together, these results suggest that the MVP-EXT factor

largely recapitulated the model from EXT1.0 (full results from GWAS and post-GWAS biological

characterization presented in the supplementary information and Supplemental Tables 2-8).

Exploring the genomic overlap between externalizing and suicide related outcomes

We next characterized the genetic overlap between MVP-EXT and suicide related phenotypes.

First, we estimated the genetic correlations between MVP-EXT and both suicide attempt (SUI)[61] and

suicidal ideation (IDE)[62]. Figure 2 (Panel A) presents genetic correlation estimates for the EUR-like and

AFR-like results side by side. Genetic correlations with SUI were strong for both the EUR-like (rG =

0.67, 95% CI = 0.60, 0.91) and AFR-like (rG = 0.74, 95% CI = 0.42, 0.81) participants. Genetic

correlations with IDE were weak, but significant in the EUR-like (rG = 0.12, 95% CI = 0.08, 0.17)

veterans and null for AFR-like (rG = -0.01, 95% CI = -0.20, 0.18) veterans. The results from MiXeR

indicated that MVP-EXT shared ~77% of its influential variants with suicide attempt. Within this shared

component, the variants that influence both MVP-EXT and suicide attempt had high sign concordance

between SNPs (79%, SE = 0.03), supporting a model in which externalizing and suicide attempt were

distinct traits with substantial polygenic overlap (full results in Supplemental Table 9).

Next, we examined the association between MVP-EXT PGS and suicide outcomes (full results

in Supplemental Table 10). The MVP-EXT PGS was positively associated with lifetime suicidal ideation

and suicide attempt in EUR-like participants from both COGA (Suicidal ideation: OR = 1.18, 95% CI =

1.11, 1.25; Suicide attempt: OR = 1.46, 95% CI = 1.32, 1.61) and Add Health (Suicidal ideation: OR =

1.07, 95% CI = 1.01, 1.13; Suicide attempt: OR = 1.13, 95% CI = 1.03, 1.24), but not the AFR-like

participants in either COGA (Suicidal ideation: OR = 0.98, 95% CI = 0.89, 1.08; Suicide attempt: OR =

1.07, 95% CI = 0.94, 1.22) or Add Health (Suicidal ideation: OR = 1.04, 95% CI = 0.93, 1.16; Suicide

attempt: OR = 0.97, 95% CI = 0.82, 1.15). For both suicidal ideation and suicide attempt, the meta-

analyzed estimate was significant (Suicidal ideation: OR = 1.09, 95% CI = 1.05, 1.13; Suicide attempt:

OR = 1.20, 95% CI = 1.13, 1.27). For context, Figure 3, Panel B presents the proportion of respondents

in COGA reporting a lifetime suicide attempt across deciles of 1) the MVP-EXT PGS and 2) EXT-factor

scores derived from the phenotypes used for replication. We see a similar pattern across predictor

(PGS vs factor scores) and population, whereby the associations are stronger in EUR-like participants.

Lastly, we examined whether the genetic architecture of externalizing converges to similar cell

type enrichment across suicide deaths vs deaths from other causes (Figure 4A). Figure 4B

demonstrates the cell-type clusters for comparison. We observed significant enrichment within

inhibitory neurons, astroglia, and oligodendrocyte progenitor cells (OPCs) in the meta-analyzed results

(Figure 4C); however, only the inhibitory neurons were significant in the AFR-like results, a finding that

is likely attributable to lower statistical power.

Prospective phenotypic analyses in electronic health records

Finally, we created counts of past 12-month externalizing codes from the time of MVP

enrollment (N = 840,865 as of 12/31/2021, overlapping with NDI time frames). Demographic

information is presented in Supplemental Table 11. Of these participants, 13.8% (N = 116,365) were

deceased by the end of 2021. Of the deceased, N = 1,268 were classified as suicides, while the more

expansive definition for deaths of despair (which includes suicide) made up N = 4,410 of the deaths.

The results from the competing risk models are presented in Table 2. Externalizing codes were

associated with both death by suicide (HR = 1.39, 95% CI = 1.33, 1.45) and the broader deaths of

despair category (HR = 1.96, 95% CI = 1.93, 2.00). In both models, the externalizing was associated

with all other causes of mortality (HR = 1.42, 95% CI = 1.41, 1.43; HR = 1.38, 95% CI = 1.38, 1.39). For

those with 4+ past year externalizing codes (compared to those with none), the 5-year cumulative

incidence for suicide death was nearly 5x greater and the 5-year cumulative incidence for deaths of

despair was almost 20x greater.

DISCUSSION

Externalizing has been consistently linked to suicide related outcomes at the phenotypic[20,63–65]

and genetic level[16,20,21,66,67], pointing to the importance of behavioral disinhibition and impulsivity in

suicidality. In the current analysis, we sought to characterize how genetic liability for externalizing is

related to suicide outcomes within the veteran population using the VA's Million Veteran Program

Cohort to further explore this overlap, using genetic data from European-like and African-like

populations. We were able to recapitulate a latent externalizing factor that overlapped strongly with

prior results (*rg* = .87) which contained no MVP data[16]. Additionally, we expanded prospective analyses

for externalizing and mortality into the full MVP sample.

We found consistent evidence for genetic overlap between externalizing and suicide-related

outcomes. Genetic correlations between MVP-EXT and suicide related outcomes across the EUR-like

and AFR-like results had similar patterns of associations. MVP-EXT was strongly associated with

suicide attempt in both populations, and results from MiXeR demonstrated that these are distinct

phenotypes that have significant polygenic overlap. While MVP-EXT was only significantly associated

with suicidal ideation in the EUR-like results, the confidence intervals overlapped with those in the AFR-

like results, suggesting that this may be the result of the lower power in the AFR-like results. In the

polygenic score analyses, the association between MVP-EXT PGS and suicide-related outcomes was

null for the AFR-like participants. There are several possible explanations for this lack of association.

First, it is possible we did not have sufficient power, as seen in the genetic correlation with ideation in

the AFR-like participants. Second, our results are primarily derived from EHR. Marginalized racial and

ethnic populations receive less engagement in EHR (e.g., fewer number of EHR actions performed

within a patient's EHR per hour) compared to those who are non-Hispanic White [68], leading to a

potentially biased assessment of externalizing. Lastly, in line with the "social push" model [69] of gene-

environment interaction, the null association could reflect the increased relevance of adverse social

conditions amongst AFR-like participants (e.g., racism, discrimination)[56–58], who are predominantly

African-American. Importantly, these are not mutually exclusive explanations.

Beyond genetic analyses, which may capture more trait-like (e.g., aggerate lifetime risk)

associations, current – as of time of enrollment – externalizing codes were associated with suicide

related mortality, potentially capturing time-dependent risk. Our analyses demonstrate that both current

and lifetime risk are important for the externalizing-suicide relationship. Importantly, the association with

MVP-EXT and suicide-related mortality remains in the context of risk for other causes of death. Given

the multitude of negative health correlates of EXT found in previous analyses of MVP (e.g., cirrhosis,

chronic airway obstruction, viral hepatitis C, etc.)[21] these results help frame the clinical importance of

externalizing beyond the specific health consequence related to substance use. Development and

implementation of externalizing risk screeners at intake may help to mitigate a variety of negative health

outcomes, including suicidality.

This research has several important limitations. First, while we utilized the largest sample of

non-European participants available in MVP, we still lacked sufficient power within the AFR-like

participants to identify loci associated with externalizing. As future releases of MVP become available, it

will be important to include larger samples and data from additional populations. Second, these

analyses focused solely on the role of genetic risk. Suicidal behaviors are complex, and social factors

(e.g., unemployment, experiences of homelessness, social support) also play an important role[56].

Future efforts should examine genomic risk factors in conjunction with well-established social and

clinical determinants of suicide-related outcomes, as has been done with SUD[70]. Third, our sample was

predominantly comprised of men (~85%) and there are large gender differences in suicidal behaviors,

especially in regard to suicide attempt vs death. Whether the results from the current analysis

generalize broadly remains an open question.

Suicide related behaviors remain a critical public health problem with a complex etiology. While

the relation between suicide with internalizing and mood-related disorders has received greater

attention, externalizing problems are an important factor in risk for suicide related behaviors. We

recapitulated here finding from a previous GWAS of externalizing problems using data derived

exclusively from MVP. Our analysis demonstrates that externalizing risk is broadly associated with

suicide attempt, with variations across populations. Importantly, current diagnoses of externalizing

problems are associated with future suicide-related mortality. Efforts at early intervention and suicide

screening should consider addressing problems related to externalizing and behavioral disinhibition in

addition to other common suicide-related risk factors.

ACKNOWLEDGEMENTS

This research is based on data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration, and was supported by MVP000. This work was also funded by grant #1I01CX001729 from the Clinical Services Research & Development (CSRD) Service of VA ORD to Drs. Beckham and Kimbrel, by the MVP CHAMPION program, which is a collaboration between the VA and the Department of Energy (DoE), and by a CSRD Senior Research Scientist award (IK6BX003777) to Dr. Beckham. Dr. Kimbrel was also supported by a VA Research Career Scientist Award (#I01BX005881) from VA ORD. Drs. Barr, Bigdeli, Aslan, and Harvey are supported by VA Cooperative Studies Program (CSP) #572. Drs. Peterson, Bigdeli, and Meyers are supported by the National Institute of Mental Health (R01MH125938). Dr. Peterson is also supported by the National Institute on Alcohol Abuse and Alcoholism (P50AA022537) and the Brain Behavior Research Foundation NARSAD grant 28632 PS Fund. Drs. Barr and Dick are also supported by the National Institute of Drug Abuse (R01DA050721) and the National Institute of Alcohol Abuse and Alcoholism (R01AA015416). Dr. Sanchez-Roige was supported by funds from the California Tobacco-Related Disease Research Program (TRDRP; Grant Number T32IR5226) and the National Institute on Drug Abuse (DP1DA054394). Dr. Mallard is supported by funds from NIH T32HG010464. This publication does not represent the views of the Department of Veteran Affairs (VA), the National Institutes of Health, or the United States Government. Dr. Barr had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation of the manuscript; and decision to submit the manuscript for publication. The MVP Publication Committee reviewed and approved the manuscript.

The Collaborative Study on the Genetics of Alcoholism (COGA), Principal Investigators B. Porjesz, V. Hesselbrock, A. Agrawal; Scientific Director, A. Agrawal; Translational Director, D. Dick, includes ten different centers: University of Connecticut (V. Hesselbrock); Indiana University (H.J. Edenberg, T.

Foroud, Y. Liu, M.H. Plawecki); University of Iowa Carver College of Medicine (S. Kuperman, A. Anderson); SUNY Downstate Health Sciences University (B. Porjesz, J. Meyers); Washington University in St. Louis (L. Bierut, A. Agrawal, S. Hartz); University of California at San Diego (M. Schuckit); Rutgers University (D. Dick, R. Hart, J. Salvatore, J. Tischfield); The Children's Hospital of Philadelphia, University of Pennsylvania (L. Almasy); Icahn School of Medicine at Mount Sinai (A. Goate, P. Slesinger); and Howard University (D. Scott). Other COGA collaborators include: C. Holzhauer, M. Hesselbrock (University of Connecticut); D. Lai, J. Nurnberger Jr., L. Wetherill, X., Xuei, S. O'Connor, (Indiana University); J. Kramer (University of Iowa), G. Chan (University of Iowa; University of Connecticut); C. Kamarajan, A. Pandey, D.B. Chorlian, P. Barr, S. Kinreich, G. Pandey, Z. Neale, S., C. Chatzinakos, J. Zhang, Saenz deViteri, R. Christian, A. Bingly (SUNY Downstate); G. Pathak (Icahn School of Medicine at Mount Sinai); A. Anokhin, K. Bucholz, F. Dong, A. Hatoum, E. Johnson, V. McCutcheon, J. Rice, S. Saccone (Washington University); F. Aliev, Z. Pang, S. Kuo, S. Brislin, J. Moore (Rutgers University); A. Merikangas (The Children's Hospital of Philadelphia and University of Pennsylvania); M. Gitik, NIAAA Staff Collaborator. We continue to be inspired by our memories of Henri Begleiter and Theodore Reich, founding PI and Co-PI of COGA, and also owe a debt of gratitude to other past organizers of COGA, including Ting- Kai Li, P. Michael Conneally, Raymond Crowe, and Wendy Reich, for their critical contributions. This national collaborative study is supported by NIH Grant U10AA008401 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the National Institute on Drug Abuse (NIDA).

We would also like to thank The Externalizing Consortium for sharing the GWAS summary statistics of externalizing. The Externalizing Consortium: Principal Investigators: Danielle M. Dick, Philipp Koellinger, K. Paige Harden, Abraham A. Palmer. Lead Analysts: Richard Karlsson Linnér, Travis T. Mallard, Peter B. Barr, Sandra Sanchez-Roige. Significant Contributors: Irwin D. Waldman. The Externalizing Consortium has been supported by the National Institute on Alcohol Abuse and Alcoholism (R01AA015416 -administrative supplement), and the National Institute on Drug Abuse

(R01DA050721). Additional funding for investigator effort has been provided by K02AA018755,

U10AA008401, P50AA022537, as well as a European Research Council Consolidator Grant (647648

EdGe to Koellinger). The content is solely the responsibility of the authors and does not necessarily

represent the official views of the above funding bodies. The Externalizing Consortium would like to

thank the following groups for making the research possible: 23andMe Inc., Add Health, Vanderbilt

University Medical Center's BioVU, Collaborative Study on the Genetics of Alcoholism (COGA), the

Psychiatric Genomics Consortium's Substance Use Disorders working group, UK10K Consortium, UK

Biobank, and Philadelphia Neurodevelopmental Cohort. We would like to thank the many studies that

made these consortia possible, the researchers involved, and the participants in those studies, without

whom this effort would not be possible. We would also like to thank the research participants and

employees of 23andMe.

This research uses data from Add Health, funded by grant P01 HD31921 (Harris) from the Eunice

Kennedy Shriver National Institute of Child Health and Human Development (NICHD), with cooperative

funding from 23 other federal agencies and foundations. Add Health is currently directed by Robert A.

Hummer and funded by the National Institute on Aging cooperative agreements U01 AG071448

(Hummer) and U01AG071450 (Aiello and Hummer) at the University of North Carolina at Chapel Hill.

Add Health was designed by J. Richard Udry, Peter S. Bearman, and Kathleen Mullan Harris at the

University of North Carolina at Chapel Hill.

Most importantly, we would like to thank the U.S. Veteran participants in MVP for their service, and for

their time, samples, and continued participation in VA research. Without them, this work would not be

possible.

CONFLICTS OF INTEREST DISCLOSURES

Dr. Dick is the Chief Scientific Officer of Thrive Genetics, Inc. Dr. Dick is also on the Advisory Board for the Seek Women's Health Company. She owns stock in both companies. She received royalties from authoring the book, The Child Code: Understanding Your Child's Unique Nature for Happier, More Effective Parenting, published by Avery, an imprint of the Penguin group. Dr Harvey reported receiving personal fees from Boehringer Ingelheim, Bioexcel, Karuna Therapeutics, Minerva Neuroscience, Alkermes, Sunovion, and Roche; royalties from WCG Endpoint Solutions; and equity from i-Function outside the submitted work. These did not impact or influence the collection, development, analysis, or interpretation of the contents of this manuscript. No other disclosures were reported.

DATA AVAILABILITY

All data sources are described in the manuscript and supplemental information. Only data from existing studies or study cohorts were analyzed, some of which have restricted access to protect the privacy of the study participants. The full summary statistics for the discovery MVP GWAS are available via dbGaP (accession: phs001672.v5.p1). Add Health genetic data can be obtained through dbGaP (accession: phs001367.v1.p1). COGA genetic data are available through dbGaP (accession: phs000763.v1.p1).

REFERENCES

1. Case A, Deaton A. Rising morbidity and mortality in midlife among white non-Hispanic Americans in the 21st century. *Proc Natl Acad Sci U S A*. 2015;112(49):15078-15083. doi:10.1073/pnas.1518393112

2. Tilstra AM, Simon DH, Masters RK. Trends in "Deaths of Despair" among Working-Aged White and Black Americans, 1990-2017. *Am J Epidemiol*. 2021;190(9):1751-1759. doi:10.1093/aje/kwab088

3. Olfson M, Blanco C, Wall M, et al. National Trends in Suicide Attempts Among Adults in the United States. *JAMA Psychiatry*. 2017;74(11):1095-1103. doi:10.1001/jamapsychiatry.2017.2582

4. Potash JB, Scott Kane MH, Chiu Y feng, et al. Attempted Suicide and Alcoholism in Bipolar Disorder: Clinical and Familial Relationships. *Am J Psychiatry*. 2000;157:12.

5. Sher L. Alcoholism and suicidal behavior: A clinical overview. *Acta Psychiatr Scand*. 2006;113(1):13-22. doi:10.1111/j.1600-0447.2005.00643.x

6. Koller G, Preuß UW, Bottlender M, Wenzel K, Soyka M. Impulsivity and aggression as predictors of suicide attempts in alcoholics. *Eur Arch Psychiatry Clin Neurosci*. 2002;252(4):155-160. doi:10.1007/s00406-002-0362-9

7. Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. *The Lancet*. 2013;382(9904):1575-1586. doi:10.1016/S0140-6736(13)61611-6

8. Modesto-Lowe V, Brooks D, Ghani M. Alcohol dependence and suicidal behavior: From research to clinical challenges. *Harv Rev Psychiatry*. 2006;14(5):241-248. doi:10.1080/10673220600975089

9. Septier M, Stordeur C, Zhang J, Delorme R, Cortese S. Association between suicidal spectrum behaviors and Attention-Deficit/Hyperactivity Disorder: A systematic review and meta-analysis. *Neurosci Biobehav Rev*. 2019;103:109-118. doi:https://doi.org/10.1016/j.neubiorev.2019.05.022

447   10.   Pompili M, Gonda X, Serafini G, et al. Epidemiology of suicide in bipolar disorders: a systematic

448   review of the literature. *Bipolar Disord*. 2013;15(5):457-490. doi:10.1111/bdi.12087

449   11.   Achenbach TM. The classification of children's psychiatric symptoms: a factor-analytic study.

450   *Psychol Monogr*. 1966;80(7):1-37. doi:10.1037/H0093906

451   12.   Kotov R, Cicero DC, Conway CC, et al. The Hierarchical Taxonomy of Psychopathology (HiTOP)

452   in   psychiatric   practice   and   research.   *Psychol   Med*.   2022;52(9):1666-1678.

453   doi:10.1017/S0033291722001301

454   13.   Anttila V, Bulik-Sullivan B, Finucane HK, et al. Analysis of shared heritability in common

455   disorders of the brain. *Science (1979)*. 2018;360(6395):eaap8757. doi:10.1126/science.aap8757

456   14.   Young SE, Stallings MC, Corley RP, Krauter KS, Hewitt JK. Genetic and environmental

457   influences on behavioral disinhibition. *Am J Med Genet*. 2000;96(5):684-695. doi:10.1002/1096-

458   8628(20001009)96:5<684::AID-AJMG16>3.0.CO;2-G

459   15.   Hicks BM, Schalet BD, Malone SM, Iacono WG, McGue M. Psychometric and Genetic

460   Architecture of Substance Use Disorder and Behavioral Disinhibition Measures for Gene

461   Association Studies. *Behav Genet*. 2011;41(4):459-475. doi:10.1007/s10519-010-9417-2

462   16.   Karlsson Linnér R, Mallard TT, Barr PB, et al. Multivariate analysis of 1.5 million people identifies

463   genetic associations with traits related to self-regulation and addiction. *Nat Neurosci*. Published

464   online 2021:1-10. doi:10.1038/s41593-021-00908-3

465   17.   Baselmans B, Hammerschlag AR, Noordijk S, et al. The Genetic and Neural Substrates of

466   Externalizing Behavior. *Biological Psychiatry Global Open Science*. 2022;2(4):389-399.

467   doi:10.1016/j.bpsgos.2021.09.007

468   18.   Clapp Sullivan ML, Schwaba T, Harden KP, Grotzinger AD, Nivard MG, Tucker-Drob EM.

469   Beyond the factor indeterminacy problem using genome-wide association data. *Nat Hum Behav*.

470   2024;8(2):205-218. doi:10.1038/s41562-023-01789-1

471   19.   Mullins N, Kang JE, Campos AI, et al. Dissecting the Shared Genetic Architecture of Suicide

472   Attempt, Psychiatric Disorders, and Known Risk Factors. *Biol Psychiatry*. 2022;91(3):313-327.

473   doi:10.1016/j.biopsych.2021.05.029

474   20.   Bigdeli TB, Barr PB, Rajeevan N, et al. Correlates of suicidal behaviors and genetic risk among

475   United States veterans with schizophrenia or bipolar I disorder. *Mol Psychiatry*. 2024;29(8):2399-

476   2407. doi:10.1038/s41380-024-02472-1

477   21.   Barr PB, Bigdeli TB, Meyers JL, et al. Correlates of Risk for Disinhibited Behaviors in the Million

478   Veteran   Program   Cohort.   *JAMA   Psychiatry*.   2024;81(2):188-197.

479   doi:10.1001/jamapsychiatry.2023.4141

480   22.   Docherty AR, Shabalin AA, DiBlasi E, et al. Genome-Wide Association Study of Suicide Death

481   and Polygenic Prediction of Clinical Antecedents. *American Journal of Psychiatry*.

482   2020;177(10):917-927. doi:10.1176/appi.ajp.2020.19101025

483   23.   Gaziano JM, Concato J, Brophy M, et al. Million Veteran Program: A mega-biobank to study

484   genetic   influences   on   health   and   disease.   *J   Clin   Epidemiol*.   2016;70:214-223.

485   doi:10.1016/j.jclinepi.2015.09.016

486   24.   Kramarow EA, Pastor PN. The health of male veterans and nonveterans aged 25-64: United

487   States, 2007-2010. *NCHS Data Brief*. 2012;(101):1-8.

488   25.   Boersma P, Cohen RA, Zelaya CE, Moy E. Multiple Chronic Conditions Among Veterans and

489   Nonveterans: United States, 2015-2018. *Natl Health Stat Report*. 2021;(153):1-13. Accessed

490   March 28, 2022. https://europepmc.org/article/med/33663648

491   26.   Hunter-Zinck H, Shi Y, Li M, et al. Genotyping Array Design and Data Quality Control in the

492   Million   Veteran   Program.   *Am   J   Hum   Genet*.   2020;106(4):535-548.

493   doi:10.1016/j.ajhg.2020.03.004

494   27.   Fang H, Hui Q, Lynch J, et al. Harmonizing Genetic Ancestry and Self-identified Race/Ethnicity in

495   Genome-wide   Association   Studies.   *Am   J   Hum   Genet*.   2019;105(4):763-772.

496   doi:10.1016/j.ajhg.2019.08.012

28. Taliun D, Harris DN, Kessler MD, et al. Sequencing of 53,831 diverse genomes from the NHLBI
TOPMed Program. *Nature*. 2021;590(7845):290-299. doi:10.1038/s41586-021-03205-y

29. Denny JC, Bastarache L, Ritchie MD, et al. Systematic comparison of phenome-wide association
study of electronic medical record data and genome-wide association study data. *Nat Biotechnol*.
2013;31(12):1102-1110. doi:10.1038/nbt.2749

30. Wu P, Gifford A, Meng X, et al. Mapping ICD-10 and ICD-10-CM codes to phecodes: Workflow
development and initial evaluation. *J Med Internet Res*. 2019;21(11):1-13. doi:10.2196/14325

31. Zheutlin AB, Dennis J, Linnér RK, et al. Penetrance and pleiotropy of polygenic risk scores for
schizophrenia in 106,160 patients across four health care systems. *American Journal of*
Psychiatry. 2019;176(10):846-855. doi:10.1176/appi.ajp.2019.18091085

32. Bigdeli TB, Voloudakis G, Barr PB, et al. Penetrance and Pleiotropy of Polygenic Risk Scores for
Schizophrenia, Bipolar Disorder, and Depression among Adults in the US Veterans Affairs
Health   Care   System.   *JAMA   Psychiatry*.   2022;79(11):1092-1101.
doi:10.1001/jamapsychiatry.2022.2742

33. Zhou W, Nielsen JB, Fritsche LG, et al. Efficiently controlling for case-control imbalance and
sample relatedness in large-scale genetic association studies. *Nat Genet*. Published online
2018:212357. doi:10.1038/s41588-018-0184-y

34. Grotzinger AD, Rhemtulla M, de Vlaming R, et al. Genomic structural equation modelling
provides insights into the multivariate genetic architecture of complex traits. *Nat Hum Behav*.
2019;3(5):513-525. doi:10.1038/s41562-019-0566-x

35. Lee PH, Anttila V, Won H, et al. Genomic relationships, novel loci, and pleiotropic mechanisms
across eight psychiatric disorders. *Cell*. 2019;179(7):1469-1482.

36. Waldman ID, Poore HE, Luningham JM, Yang J. Testing structural models of psychopathology
at the genomic level. *World Psychiatry*. Published online 2020. doi:10.1002/wps.20772

37. Luo Y, Li X, Wang X, et al. Estimating heritability and its enrichment in tissue-specific gene sets
in admixed populations. *Hum Mol Genet*. 2021;30(16):1521-1534. doi:10.1093/hmg/ddab130

38. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of

genetic associations with FUMA. *Nat Commun.* 2017;8(1):1-11. doi:10.1038/s41467-017-01261-

5

39. Frei O, Holland D, Smeland OB, et al. Bivariate causal mixture model quantifies polygenic

overlap between complex traits beyond genetic correlation. *Nat Commun.* 2019;10(1):2417.

doi:10.1038/s41467-019-10310-0

40. Zhang MJ, Hou K, Dey KK, et al. Polygenic enrichment distinguishes disease associations of

individual cells in single-cell RNA-seq data. *Nat Genet.* 2022;54(10):1572-1580.

doi:10.1038/s41588-022-01167-z

41. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: Generalized Gene-Set Analysis of

GWAS Data. *PLoS Comput Biol.* 2015;11(4):e1004219. doi:10.1371/journal.pcbi.1004219

42. Friedman MJ, Huber BR, Brady CB, et al. VA's National PTSD Brain Bank: a National Resource

for Research. *Curr Psychiatry Rep.* 2017;19(10):73. doi:10.1007/s11920-017-0822-6

43. Chatzinakos C, Pernia CD, Morrison FG, et al. Single-Nucleus Transcriptome Profiling of

Dorsolateral Prefrontal Cortex: Mechanistic Roles for Neuronal Gene Expression, Including the

17q21.31 Locus, in PTSD Stress Response. *American Journal of Psychiatry.* 2023;180(10):739-

754. doi:10.1176/appi.ajp.20220478

44. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful

Approach to Multiple Testing. *Journal of the Royal Statistical Society Series B (Methodological).*

1995;57(1):289-300. http://www.jstor.org/stable/2346101

45. Agrawal A, Brislin SJ, Bucholz KK, et al. The Collaborative Study on the Genetics of Alcoholism:

Overview. *Genes Brain Behav.* 2023;22(5):e12864. doi:10.1111/gbb.12864

46. Begleiter H. The Collaborative Study on the Genetics of Alcoholism. *Alcohol Health Res World.*

1995;19(3):228-236.

47. Dick DM, Balcke E, McCutcheon V, et al. The collaborative study on the genetics of alcoholism:

Sample and clinical data. *Genes Brain Behav.* 2023;22(5):e12860. doi:10.1111/gbb.12860

549 48. Bucholz KK, Cadoret R, Cloninger CR, et al. A new, semi-structured psychiatric interview for use

550   in genetic linkage studies: a report on the reliability of the SSAGA. *J Stud Alcohol*.

551   1994;55(2):149-158.

552 49. Johnson EC, Salvatore JE, Lai D, et al. The collaborative study on the genetics of alcoholism:

553   Genetics. *Genes Brain Behav*. 2023;22(5):e12856. doi:10.1111/gbb.12856

554 50. Harris KM, Halpern CT, Whitsel E, et al. The National Longitudinal Study of Adolescent to Adult

555   Health: research design. *Add Health: The National Longitudinal Study of Adolescent to Adult*

556   *Health*. Published online 2009. http://www.cpc.unc.edu/projects/addhealth/design

557 51. Ruan Y, Lin YF, Feng YCA, et al. Improving polygenic prediction in ancestrally diverse

558   populations. *Nat Genet*. 2022;54(5):573-580. doi:10.1038/s41588-022-01054-7

559 52. Ding Y, Hou K, Xu Z, et al. Polygenic scoring accuracy varies across the genetic ancestry

560   continuum. *Nature*. 2023;618(7966):774-781. doi:10.1038/s41586-023-06079-4

561 53. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models.

562   *Stat Med*. 2007;26(11):2389-2430. doi:https://doi.org/10.1002/sim.2712

563 54. Terry M. Therneau, Patricia M. Grambsch. *Modeling Survival Data: Extending the Cox Model*.

564   Springer; 2000.

565 55. Therneau TM. A Package for Survival Analysis in R. Published online 2024. https://CRAN.R-

566   project.org/package=survival

567 56. Blosnich JR, Montgomery AE, Dichter ME, et al. Social Determinants and Military Veterans'

568   Suicide Ideation and Attempt: a Cross-sectional Analysis of Electronic Health Record Data. *J*

569   *Gen Intern Med*. 2020;35(6):1759-1767. doi:10.1007/s11606-019-05447-z

570 57. Coimbra BM, Hoeboer CM, Yik J, Mello AF, Mello MF, Olff M. Meta-analysis of the effect of racial

571   discrimination on suicidality. *SSM Popul Health*. 2022;20:101283.

572   doi:https://doi.org/10.1016/j.ssmph.2022.101283

58.   Paradies Y, Ben J, Denson N, et al. Racism as a Determinant of Health: A Systematic Review

and Meta-Analysis. *PLoS One.* 2015;10(9):e0138511-.

https://doi.org/10.1371/journal.pone.0138511

59.   Peterson RE, Kuchenbaecker K, Walters RK, et al. Genome-wide Association Studies in

Ancestrally Diverse Populations: Opportunities, Methods, Pitfalls, and Recommendations. *Cell.*

2019;179(3):589-603. doi:10.1016/j.cell.2019.08.051

60.   Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide

association scans. *Bioinformatics.* 2010;26(17):2190-2191. doi:10.1093/bioinformatics/btq340

61.   Docherty AR, Mullins N, Ashley-Koch AE, et al. GWAS Meta-Analysis of Suicide Attempt:

Identification of 12 Genome-Wide Significant Loci and Implication of Genetic Risks for Specific

Health Factors. *American Journal of Psychiatry.* 2023;180(10):723-738.

doi:10.1176/appi.ajp.21121266

62.   Ashley-Koch AE, Kimbrel NA, Qin XJ, et al. Genome-wide association study identifies four pan-

ancestry loci for suicidal ideation in the Million Veterans Program. *PLoS Genet.*

2023;19(3):e1010623. doi:10.1371/journal.pgen.1010623

63.   Edwards AC, Ohlsson H, Sundquist J, et al. The role of substance use disorders in the transition

from suicide attempt to suicide death: a record linkage study of a Swedish cohort. *Psychol Med.*

2024;54(1):90-97. doi:10.1017/S0033291722002240

64.   Ferrari AJ, Norman RE, Freedman G, et al. The burden attributable to mental and substance use

disorders as risk factors for suicide: Findings from the Global Burden of Disease Study 2010.

PLoS One. 2014;9(4):e91936. doi:10.1371/journal.pone.0091936

65.   Lannoy S, Ohlsson H, Kendler KS, et al. Risk of suicidal behavior as a function of alcohol use

disorder typologies: A Swedish population-based study. *Addiction.* 2024;119(2):281-290.

doi:10.1111/add.16351

66. Colbert SMC, Hatoum AS, Shabalin A, et al. Exploring the genetic overlap of suicide-related

behaviors and substance use disorders. *American Journal of Medical Genetics, Part B:*

Neuropsychiatric Genetics. 2021;186(8):445-455. doi:10.1002/ajmg.b.32880

67. Colbert SMC, Mullins N, Chan G, et al. Polygenic Contributions to Suicidal Thoughts and

Behaviors in a Sample Ascertained for Alcohol Use Disorders. *Complex Psychiatry*. 2023;9(1-

4):11-23. doi:10.1159/000529164

68. Yan C, Zhang X, Yang Y, et al. Differences in Health Professionals' Engagement With Electronic

Health Records Based on Inpatient Race and Ethnicity. *JAMA Netw Open*.

2023;6(10):e2336383-e2336383. doi:10.1001/jamanetworkopen.2023.36383

69. Boardman JD, Daw J, Freese J. Defining the environment in gene-environment research:

Lessons from social epidemiology. *Am J Public Health*. 2013;103(SUPPL.1):S64--S72.

doi:10.2105/AJPH.2013.301355

70. Barr PB, Driver MN, Kuo SIC, et al. Clinical, environmental, and genetic risk factors for

substance use disorders: characterizing combined effects across multiple cohorts. *Mol*

Psychiatry. 2022;27(11):4633-4641. doi:10.1038/s41380-022-01801-6

FIGURE CAPTIONS

Figure 1: Multivariate GWAS models of externalizing in MVP.

Final models for EUR-like (Panel A) and AFR-like (Panel B) populations used in the subsequent multivariate GWASs. *Df* = degrees of freedom. AIC = Akaike's information criterion, CFI = comparative fit index, SRMR = standardized root mean squared residual.

Figure 2: Genetic correlations across populations.

Genetic correlations (and 95% confidence intervals) between MVP-EXT and suicide attempt (SUI) and suicidal ideation (IDE) for both European-like and African-like results (Panel A). Genetic overlap between MVP-EXT and SUI using bivariate MiXeR in European-like results (Panel B). Venn diagram depicting the estimated number of influencing variants in thousands shared (grey) between and unique to suicide attempt (SUI, blue) and externalizing (MVP-EXT, orange). Conditional quantile–quantile (Q–Q) plots show observed versus expected -log10 p values in SUI and MVP-EXT as a function of the significance of association with the other trait. Log likelihood curves show goodness of model fit as a function of the count of shared influential variants.

Figure 3: Polygenic associations between MVP-EXT PGS in COGA and Add Health.

European-like, African-like, and meta-analysis associations between MVP-EXT PGS and suicide attempt (SUI) and suicidal ideation (IDE) in COGA and Add Health (Panel A). Proportion of individuals reporting lifetime suicide attempt across MVP-EXT PGS deciles (left) and phenotypic factor score deciles (right) in European-like and African-like COGA participants (Panel B).

Figure 4: Cell-type enrichment for MVP-EXT results in post-mortem brain tissue.

Cell type enrichment across suicide deaths vs deaths from other causes (Panel A). Cell-type clusters (Panel B). Tests for cell-type enrichment across European-like, African-like, and meta-analysis results (Panel C).

640 **TABLE 1: EXTERNALIZING PHENOTYPES INCLUDED IN THE MULTIVARIATE GWAS**

Label	Population	Description	Source	N (eff)	h^2_{SNP} (SE)	LDSC int.	Mean χ^2	λ_{GC}
ADHD	EUR-like	Attention deficit hyperactivity disorder	EHR	41,861	0.073 (0.013)	1.014	1.076	1.071
AUD	EUR-like	Alcohol use disorder	EHR	249,476	0.101 (0.005)	1.024	1.529	1.414
DUD	EUR-like	Drug use disorder	EHR	175,636	0.113 (0.005)	1.036	1.435	1.350
TUD	EUR-like	Tobacco use disorder	EHR	365,610	0.091 (0.003)	1.065	1.749	1.570
SMOK	EUR-like	Ever smoker	Survey	181,724	0.114 (0.005)	1.009	1.559	1.424
BINGE	EUR-like	Binge drinking frequency	Survey	191,545	0.053 (0.004)	1.035	1.238	1.216
ADHD	AFR-Like	Attention deficit hyperactivity disorder	EHR	3,753	0.096 (0.070)	0.999	1.011	1.008
AUD	AFR-Like	Alcohol use disorder	EHR	94,280	0.050 (0.006)	1.008	1.154	1.139
DUD	AFR-Like	Drug use disorder	EHR	87,879	0.049 (0.006)	1.016	1.150	1.140
TUD	AFR-Like	Tobacco use disorder	EHR	102,346	0.049 (0.005)	1.010	1.172	1.155
SMOK	AFR-Like	Ever smoker	Survey	45,638	0.050 (0.008)	0.998	1.071	1.061
BINGE	AFR-Like	Binge drinking frequency	Survey	32,627	0.055 (0.011)	1.030	1.088	1.094

641 All statistics estimated using LD Score regression. N (eff) = effective sample size (4/[[1/N Cases] + [1/N

642 Controls]], h^2_{SNP} = observed scale SNP-based heritability, LDSC int = LD Score regression intercept,

643 Mean χ2 = mean χ2 statistic. λ_{GC} = genomic inflation factor (median χ2 statistic divided by the expected

644 median of the χ2 distribution with 1 df).

TABLE 2: COMPETING RISK MODELS AND 5-YEAR CUMULATIVE INCIDENCE FOR COUNT OF EXTERNALIZING DIAGNOSES AND SUICIDE-RELATED MORTALITY

Outcome	HR/Cumulative incidence	95% CI	95% CI	P-value
Suicide death	1.39	1.33	1.45	6.18×10^{-51}
5-year cumulative incidence:				
0 externalizing codes	0.10%	10.77%	10.95%	-
1-3 externalizing codes	0.20%	13.50%	13.80%	-
4+ externalizing codes	0.48%	14.76%	15.83%	-
All other deaths	1.42	1.41	1.43	2.23×10^{-308}
5-year cumulative incidence:				
0 externalizing codes	10.86%	0.09%	0.11%	-
1-3 externalizing codes	13.65%	0.18%	0.22%	-
4+ externalizing codes	15.30%	0.38%	0.58%	-
Death of despair	1.96	1.93	2.00	2.23×10^{-308}
5-year cumulative incidence:				
0 externalizing codes	0.19%	0.18%	0.20%	-
1-3 externalizing codes	0.91%	0.87%	0.95%	-
4+ externalizing codes	3.65%	3.37%	3.93%	-
All other deaths	1.38	1.38	1.39	2.23×10^{-308}
5-year cumulative incidence:				
0 externalizing codes	10.78%	10.69%	10.86%	-
1-3 externalizing codes	12.93%	12.78%	13.08%	-
4+ externalizing codes	12.13%	11.64%	12.61%	-

HR = hazard ratio. CI = confidence interval. Lists of ICD-10 codes for suicide death and deaths of despair listed in Supplemental Table 1. All competing risk models covaried for age (at enrollment), gender, and race-ethnicity.

A

Fit:
Chi-squared = 104.10
df = 7
p = 1.53x10^{-19}
AIC = 132.10
CFI = 0.99
SRMR = 0.06

MVP EXT
(EUR-like)

0.86 — AUD
0.65 — BINGE
0.75 — TUD
0.56 — SMOK
0.98 — DUD
0.19 — ADHD

B

Fit:
Chi-squared = 131.51
df = 8
p = 1.38x10^{-24}
AIC = 157.51
CFI = 0.96
SRMR = 0.09

MVP EXT
(AFR-like)

0.80 — AUD
0.48 — BINGE
0.89 — TUD
0.94 — DUD
0.23 — MOS ATTN